Лечащий врач · Sep 24, 2026
Alphaherpesviruses and neurodegeneration: from molecular mechanisms of persistence to clinical preventive strategies
By Pushkina P, Владимировна МИ, Oganyan V et al.
Background. Alphaherpesviruses – herpes simplex virus 1 and 2, as well as the varicella-zoster virus – have the ability to persist in neurons for life and reactivate, which links them to the risk of developing neurodegenerative diseases, primarily Alzheimer's disease and vascular dementia. Neurodegenerative processes are the most common cause of cognitive decline. Alzheimer's disease is the most common form of dementia, characterized by extracellular accumulation of beta-amyloid and intracellular aggregation of hyperphosphorylated tau protein, leading to synaptic dysfunction and neuronal death. Objective. The purpose of this review is to systematize current understanding of the molecular mechanisms linking alphaherpesviruses to neurodegeneration, the pathophysiology of the process, and to characterize current therapeutic approaches. Results. Over the past five years, numerous studies have been published clarifying the molecular mechanisms of this connection: from modulation of the cGAS-STING pathway and mitochondrial dysfunction to epigenetic remodeling and the spread of pathological proteins through extracellular vesicles. This review systematizes current data on the role of alphaherpesviruses in the pathogenesis of neurodegeneration, focusing on the molecular mechanisms of immune escape, stress-induced reactivation, and intercellular spread of tau protein. It also demonstrates the role of extracellular vesicles in the pathogenesis of neurodegeneration. Particular attention is paid to the role of APOE4 as a modulator of virus-induced pathology, the phenomenon of herpesvirus coinfection, biomarkers for risk stratification, as well as conflicting results from clinical trials of antiviral drugs and growing evidence of the protective role of herpes zoster vaccination. The review concludes with practical recommendations for clinicians and an analysis of the limitations of current research, which highlight recommendations for herpes zoster vaccination for all individuals over 50 years of age; timely initiation of antiviral therapy during herpes zoster episodes, which significantly reduces the risk of developing postherpetic neuralgia and late-onset dementia; and the lack of effectiveness of routine antiviral therapy for the treatment of already diagnosed Alzheimer's disease.